Tag: Policy + Advocacy Updates

This week CBSA partnered with LivaNova to host Senator Cory Gardner at LivaNova’s Arvada facility. The event included a brief meeting with the Senator and his staff, followed by a tour of the facility...

New results highlight success of state-funded grant program for early-stage life science companies DENVER – Colorado BioScience Association (CBSA) brings healthcare innovators to the state Capitol to...

This week, CBSA attended a stakeholder meeting on House Bill 1131, Prescription Drug Cost Education. As the bill is currently written; it requires a drug manufacturer, wholesaler, agent or an employee...

On Tuesday President Trump gave his State of the Union address, in which he described the need to rein in health care costs as a major priority. The President also laid out an ambitious health care ag...

Roberts to Oversee Policy and Communications at Life Science Organization DENVER – Colorado BioScience Association (CBSA) announces the appointment of Emily Roberts to vice president. Roberts takes ov...

Yesterday the Colorado BioScience Association testified in opposition to Senate Bill 005, which tasks the department of health care policy and financing to design a program to import prescription phar...

Colorado BioScience Association is focused on increasing our companies’ access to capital and highlighting the innovative work coming out of our state. Our team recently collaborated with the Denver B...

Last week CBSA took an opposition position to Senate Bill 005 – Import Prescription Drugs from Canada. As a reminder this bill would create the "Colorado Wholesale Importation of Prescription Drugs Ac...

This marks the first full week of the 72nd First Regular Session of the Colorado General Assembly. It was a busy week with bill introductions, Governor Polis’ Inauguration and the State of the State (...

Today, January 4, 2019 marks the first of 120 days of the 72nd General Assembly. CBSA looks forward to advocating on behalf of our members, industry and the patients we serve. We also look forward to...